Submit a comment
Abstract
The induced membrane technique (IMT) is a 2-stage surgical intervention for critical-sized bone defects (CSBD), yet the metabolic mechanisms driving neovascularization within the induced membrane remain unclear. Here, we combined a rat IMT model, metabolomic profiling, and endothelial assays to delineate the role of purine metabolism in neovascularization of type H vessels. Using a rat IMT model and metabolomic profiling, we identified purine metabolism as the most substantial pathway during the formation of induced membranes, with consistent trends of adenosine, inosine, hypoxanthine, and xanthosine found in both serum and induced membranes. Histological analysis revealed abundant CD31hiEMCNhi type H vessels, critical for osteogenesis, within the induced membrane. Inhibition of purine metabolism suppressed the CD31hiEMCNhi type H phenotype in human umbilical vein endothelial cells, whereas treatment with inosine, hypoxanthine, or xanthosine promoted endothelial activation and the type H phenotype. Notably, inosine and hypoxanthine displayed parallel changes across consistent systemic (serum) and local alterations (induced membranes), highlighting their potential as serum indicators of induced membrane formation. Collectively, these findings uncover a previously unrecognized metabolic mechanism driving neovascularization of type H vessels in induced membranes and suggest purine metabolites as promising indicators and therapeutic targets for improving IMT outcomes as well as CBSD treatment.
Authors
Yung-Heng Hsu, Guan-Lin Lee, Yu-Chih Lin, Mei-Feng Chen, Yuhan Chang, Ying-Yu Wu, Chih-Chien Hu
Guidelines
The Editorial Board will only consider comments that are deemed relevant and of interest to readers. The Journal will not post data that have not been subjected to peer review; or a comment that is essentially a reiteration of another comment.
- Comments appear on the Journal’s website and are linked from the original article’s web page.
- Authors are notified by email if their comments are posted.
- The Journal reserves the right to edit comments for length and clarity.
- No appeals will be considered.
- Comments are not indexed in PubMed.
Specific requirements
- Maximum length, 400 words
- Entered as plain text or HTML
- Author’s name and email address, to be posted with the comment
- Declaration of all potential conflicts of interest (even if these are not ultimately posted); see the Journal’s conflict-of-interest policy
- Comments may not include figures
